documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
2,645 rows where agency_id = "FDA" and posted_year = 2006 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_month, open_for_comment, withdrawn, posted_date (date), comment_start_date (date), last_modified (date)
document_type 5
- Other 1,449
- Supporting & Related Material 635
- Notice 526
- Proposed Rule 18
- Rule 17
posted_year 1
- 2006 · 2,645 ✖
agency_id 1
- FDA · 2,645 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2006-P-0325-0002 | FDA | Amend 21 C.F.R. 312. Promotion & Charging for Investigational Drugs Re: Pandemic Vaccine-CLOSED FDA-2006-P-0325 | Acknowledgement Letter from FDA DMB to Vaccine for All LLC | Other | Acknowledgement Letter/Receipt | 2006-12-29T05:00:00Z | 2006 | 12 | 2024-12-10T17:14:33Z | 0 | 0 | 090000648045ce8c | |||
| FDA-2006-N-0100-0018 | FDA | FDA-Regulated Products Containing Nanotechnology Materials FDA-2006-N-0100 | National Cancer Institute | Other | TS-Testimony | 2006-12-29T05:00:00Z | 2006 | 12 | 2008-04-11T23:09:24Z | 0 | 0 | 090000648044504a | |||
| FDA-2006-P-0325-0001 | FDA | Amend 21 C.F.R. 312. Promotion & Charging for Investigational Drugs Re: Pandemic Vaccine-CLOSED FDA-2006-P-0325 | Acknowledgement Letter from FDA DMB to Vaccine for All LLC | Other | Acknowledgement Letter/Receipt | 2006-12-29T05:00:00Z | 2006 | 12 | 2024-12-10T17:14:04Z | 0 | 0 | 090000648045ce69 | |||
| FDA-2003-N-0385-0002 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | Draft Guidance | Supporting & Related Material | GDL-Guidance | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-12T01:04:22Z | 0 | 0 | 090000648049a5e6 | |||
| FDA-2003-N-0385-0006 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | Risk Assessment | Supporting & Related Material | RA-Regulatory Assessment | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-12T01:04:22Z | 0 | 0 | 090000648049a5fe | |||
| FDA-2006-P-0003-0003 | FDA | Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 | FDA/OC to CoMed, Coalition for Mercury-Free Drugs | Other | LET-Letter | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-11T23:16:24Z | 0 | 0 | 09000064804413d6 | |||
| FDA-2003-N-0385-0003 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | Draft Guidance | Supporting & Related Material | GDL-Guidance | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-12T01:06:16Z | 0 | 0 | 090000648049a5f7 | |||
| FDA-2006-P-0003-0001 | FDA | Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 | FDA/DDM to CoMed, Coalition for Mercury-Free Drugs | Other | ACK-Acknowledgement Letter | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-11T23:16:24Z | 0 | 0 | 09000064804413a7 | |||
| FDA-2004-P-0001-0007 | FDA | Citizen Petition Requesting Certain Actions with Respect to Vaccines & Other Drug Products, Containing Added Mercury, In Order to Reduce the Health Risk to Susceptible Fetuses, Newborns, Children, Adolescents & Adults-CLOSED FDA-2004-P-0001 | FDA/CBER Response to Coalition for Mercury-Free Drugs (CoMeD) - Answer | Other | ANS-Answer | 2006-12-28T05:00:00Z | 2006 | 12 | 2009-10-19T19:01:20Z | 0 | 0 | 090000648046a67e | |||
| FDA-2003-N-0385-0001 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | FDA | Notice | NAD-Notice of Availability of Data | 2006-12-28T05:00:00Z | 2006 | 12 | 2006-12-28T05:00:00Z | 2007-04-03T03:59:59Z | 2008-04-12T01:03:44Z | 0 | 0 | 090000648049a462 | |
| FDA-2006-P-0003-0002 | FDA | Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 | FDA/DDM to CoMed, Coalition for Mercury-Free Drugs | Other | ACK-Acknowledgement Letter | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-11T23:16:23Z | 0 | 0 | 09000064804413d5 | |||
| FDA-1996-N-0028-0037 | FDA | Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Supplements FDA-1996-N-0028 | FDA Office of Policy to the Docket, 12/26/2006 (re Meeting on September 20, 2006 between the Food and Drug Administration and the Natural Products Association) - Memorandum Meeting | Other | MM-Memorandum of Meeting | 2006-12-28T05:00:00Z | 2006 | 12 | 2009-09-11T19:52:51Z | 0 | 0 | 09000064804fbfa5 | |||
| FDA-2003-N-0385-0004 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | Risk Management Plan | Supporting & Related Material | BKG-Background Material | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-12T01:05:02Z | 0 | 0 | 090000648049a5f9 | |||
| FDA-2003-N-0385-0005 | FDA | Draft Animal Cloning Risk Assessment re FDA-2008-N-0033 FDA-2003-N-0385 | Risk Management Plan | Supporting & Related Material | BKG-Background Material | 2006-12-28T05:00:00Z | 2006 | 12 | 2008-04-12T01:06:52Z | 0 | 0 | 090000648049a5fc | |||
| FDA-1996-N-0028-0038 | FDA | Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Supplements FDA-1996-N-0028 | See FDA-1996-N-0028-0037 | Supporting & Related Material | 2006-12-28T00:00:00Z | 2006 | 12 | 2009-09-11T20:46:58Z | 0 | 1 | 09000064804fbfa7 | ||||
| FDA-2006-P-0344-0002 | FDA | FDA-2006-P-0344 | Acknowledgment Letter from FDA DMB to King & Spalding LLP | Other | Acknowledgement Letter/Receipt | 2006-12-27T05:00:00Z | 2006 | 12 | 2024-12-10T15:26:25Z | 0 | 0 | 090000648045f14e | |||
| FDA-2006-P-0344-0001 | FDA | FDA-2006-P-0344 | Acknowledgment Letter from FDA DMB to King & Spalding LLP | Other | Acknowledgement Letter/Receipt | 2006-12-27T05:00:00Z | 2006 | 12 | 2024-12-10T15:25:34Z | 0 | 0 | 090000648045f12b | |||
| FDA-2006-P-0146-0002 | FDA | ANDA for Sterile Vancomycin Hydrochloride USP, 750 mg-CLOSED FDA-2006-P-0146 | Acknowledgment Letter from FDA DMB to King and Spalding, LLP | Other | Acknowledgement Letter/Receipt | 2006-12-27T05:00:00Z | 2006 | 12 | 2024-12-10T16:05:27Z | 0 | 0 | 09000064804504bc | |||
| FDA-2006-P-0146-0001 | FDA | ANDA for Sterile Vancomycin Hydrochloride USP, 750 mg-CLOSED FDA-2006-P-0146 | Acknowledgment Letter from FDA DMB to King and Spalding, LLP | Other | Acknowledgement Letter/Receipt | 2006-12-27T05:00:00Z | 2006 | 12 | 2024-12-10T16:01:23Z | 0 | 0 | 09000064804504ab | |||
| FDA-2006-E-0322-0001 | FDA | Patent Extension Application for Anthelios SX Daily Moisturizing Cream With Sunscreen, U.S. Patent No. 4,585,597 FDA-2006-E-0322 | U.S. Patent and Trademark Office to FDA/CDER (HFD-7) | Other | LET-Letter | 2006-12-26T05:00:00Z | 2006 | 12 | 2008-04-11T23:07:56Z | 0 | 0 | 090000648045cce0 | |||
| FDA-2005-P-0313-0004 | FDA | FDA to Refuse to Approve ANDA or Section 505(b)(2), for Inhalation Drug Products Containing A Combination of the Active Ingredients Albuterol Sulfate & Ipratropium Hydrochloirde Administered by Nebulization for the Treatment of Chronic Pulmonary Obstructive Disorder-CLOSED FDA-2005-P-0313 | Petition Denial from FDA CDER to Charles J. Raubicheck | Other | Denial | 2006-12-26T05:00:00Z | 2006 | 12 | 2024-12-16T16:54:26Z | 0 | 0 | 0900006480447a06 | |||
| FDA-2006-P-0074-0007 | FDA | To Exempt the Class II device Cranial Orthoses from Premarket Notification Requirements under section 510(m)(2)-CLOSED FDA-2006-P-0074 | FDA | Notice | N-Notice | 2006-12-26T05:00:00Z | 2006 | 12 | 2006-12-22T05:00:00Z | 2008-04-11T23:17:41Z | 0 | 0 | 0900006480444652 | ||
| FDA-2006-E-0506-0002 | FDA | Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,614,560 FDA-2006-E-0506 | Letter from U.S. Patent and Trademark Office to FDA CDER | Other | Letter(s) | 2006-12-26T05:00:00Z | 2006 | 12 | 2026-01-06T20:55:50Z | 0 | 0 | 090000648046399d | |||
| FDA-2006-E-0506-0001 | FDA | Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,614,560 FDA-2006-E-0506 | Letter from U.S. Patent and Trademark Office to FDA CDER | Other | Letter(s) | 2006-12-26T05:00:00Z | 2006 | 12 | 2026-01-06T20:53:27Z | 0 | 0 | 0900006480463997 | |||
| FDA-2000-V-0069-0001 | FDA | Laser Light Show FDA-2000-V-0069 | FDA/CDRH to Level Entertainment, LLC - Approval for Variance | Other | Approval for Variance (VRA) | 2006-12-26T05:00:00Z | 2006 | 12 | 2025-07-30T17:21:44Z | 0 | 0 | 09000064804b00bf | |||
| FDA-2006-E-0125-0002 | FDA | Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,061,703 FDA-2006-E-0125 | Request for Certificate of Correction from U.S. Patent and Trademark Office | Other | Letter(s) | 2006-12-26T05:00:00Z | 2006 | 12 | 2026-01-06T19:13:42Z | 0 | 0 | 09000064804501c7 | |||
| FDA-2005-P-0125-0004 | FDA | Over-the Counter Sale of Modafinil-CLOSED FDA-2005-P-0125 | Petition Denial from FDA CDER to James Salsman | Other | Denial | 2006-12-26T05:00:00Z | 2006 | 12 | 2024-12-13T20:25:39Z | 0 | 0 | 090000648043fc52 | |||
| FDA-2006-E-0125-0001 | FDA | Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,061,703 FDA-2006-E-0125 | Letter from U.S. Patent and Trademark Office to FDA CDER | Other | Letter(s) | 2006-12-26T05:00:00Z | 2006 | 12 | 2026-01-06T19:09:03Z | 0 | 0 | 09000064804501bf | |||
| FDA-1999-V-0028-0002 | FDA | Laser Light Show Projector Model #LP1 FDA-1999-V-0028 | Center for Devices and Radiological Health to John's Laser Productions - Approval for Variance | Other | Approval for Variance (VRA) | 2006-12-26T05:00:00Z | 2006 | 12 | 2025-04-21T20:30:07Z | 0 | 0 | 09000064804a5c96 | |||
| FDA-2006-D-0032-0005 | FDA | Guidance for Clinical Investigators, Institutional Review Boards and Sponsors Process for Handling Referrals to FDA Under 21 CFR 50.54 : Additional Safeguards for Children in Clinical Investigations FDA-2006-D-0032 | FDA | Notice | NAD-Notice of Availability of Data | 2006-12-22T05:00:00Z | 2006 | 12 | 2006-12-21T05:00:00Z | 2008-04-11T22:52:06Z | 0 | 0 | 09000064804420d6 | ||
| FDA-1997-S-0006-0227 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Holistic Therapies | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:05Z | 0 | 0 | 09000064805c995e | |||
| FDA-1997-S-0006-0229 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Tronex Company | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:03Z | 0 | 0 | 09000064805c9960 | |||
| FDA-1997-S-0006-0231 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Calgenex Corporation | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:09Z | 0 | 0 | 09000064805c9962 | |||
| FDA-1997-S-0006-0230 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Enzymatic Therapy Inc | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:06:57Z | 0 | 0 | 09000064805c9961 | |||
| FDA-1997-S-0006-0228 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Tronex Company | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:06:55Z | 0 | 0 | 09000064805c995f | |||
| FDA-1997-S-0006-0226 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Flora Inc | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:01Z | 0 | 0 | 09000064805c995d | |||
| FDA-2006-D-0032-0007 | FDA | Guidance for Clinical Investigators, Institutional Review Boards and Sponsors Process for Handling Referrals to FDA Under 21 CFR 50.54 : Additional Safeguards for Children in Clinical Investigations FDA-2006-D-0032 | Guidance | Supporting & Related Material | GDL-Guidance | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-04-11T22:52:06Z | 0 | 0 | 09000064804420d8 | |||
| FDA-2006-N-0042-0002 | FDA | Medical Device Regulations; Disqualification of a Clinical Investigator; Technical Amendment FDA-2006-N-0042 | Medical Device Regulations; Disqualification of a Clinical Investigator; Technical Amendment (DUPLICATE) | Notice | Notice of Final Rule | 2006-12-22T05:00:00Z | 2006 | 12 | 2006-12-22T05:00:00Z | 2025-07-09T00:26:29Z | E6-21952 | 0 | 0 | 09000064804428d5 | |
| FDA-1997-S-0006-0232 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to World Nutrition Inc | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:09Z | 0 | 0 | 09000064805c9963 | |||
| FDA-2006-N-0042-0001 | FDA | Medical Device Regulations; Disqualification of a Clinical Investigator; Technical Amendment FDA-2006-N-0042 | Medical Device Regulations; Disqualification of a Clinical Investigator; Technical Amendment | Notice | Notice of Final Rule | 2006-12-22T05:00:00Z | 2006 | 12 | 2006-12-22T05:00:00Z | 2025-07-09T00:24:56Z | E6-21952 | 0 | 0 | 09000064804428d6 | |
| FDA-1997-S-0006-0225 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | FDA/CFSAN to Enzymatic Therapy Inc | Other | LET-Letter | 2006-12-22T05:00:00Z | 2006 | 12 | 2008-05-16T22:07:07Z | 0 | 0 | 09000064805c995c | |||
| FDA-2006-P-0346-0004 | FDA | FDA-2006-P-0346 | Corrected Acknowledgement Letter to Endo Pharmaceuticals Inc | Other | Correction(s) | 2006-12-21T05:00:00Z | 2006 | 12 | 2012-04-18T22:53:07Z | 0 | 0 | 090000648045f269 | |||
| FDA-2005-D-0027-0003 | FDA | Guidance for Industry and Food and Drug Administration: Procedures for Handling Post-Approval Studies Imposed by PMA Order FDA-2005-D-0027 | Guideline | Supporting & Related Material | GDL-Guidance | 2006-12-21T05:00:00Z | 2006 | 12 | 2008-04-11T23:46:25Z | 0 | 0 | 090000648043e842 | |||
| FDA-2006-P-0346-0003 | FDA | FDA-2006-P-0346 | See FDA-2006-P-0346-0004 | Supporting & Related Material | Correction | 2006-12-21T05:00:00Z | 2006 | 12 | 2012-04-18T23:13:08Z | 0 | 0 | 090000648045f268 | |||
| FDA-1978-N-0023-0020 | FDA | Skin Bleaching Drug Products- OPEN FDA-1978-N-0023 | Memorandum of Telephone Conversation between FDA/CDER and Venable, LLP | Other | Memorandum | 2006-12-21T05:00:00Z | 2006 | 12 | 2019-09-16T13:06:41Z | 0 | 0 | 090000648055fba3 | |||
| FDA-2005-D-0027-0004 | FDA | Guidance for Industry and Food and Drug Administration: Procedures for Handling Post-Approval Studies Imposed by PMA Order FDA-2005-D-0027 | FDA | Notice | NAD-Notice of Availability of Data | 2006-12-21T05:00:00Z | 2006 | 12 | 2006-12-20T05:00:00Z | 2008-04-11T23:46:25Z | 0 | 0 | 090000648043e843 | ||
| FDA-2004-P-0278-0004 | FDA | Petition to Require Restaurants to Indicate That the Food they Serve Contains Trans Fat From Partially Hydrogenated Vegetable Oils-CLOSED FDA-2004-P-0278 | Citizen Petition Denial from FDA CFSAN to the Center for Science in the Public Interest (CSPI) | Other | PDN-Petition Denial | 2006-12-21T05:00:00Z | 2006 | 12 | 2006-12-15T05:00:00Z | 2025-02-19T16:56:00Z | 0 | 0 | 090000648047269b | ||
| FDA-2002-P-0246-0001 | FDA | Print Clear, Legible & Intelligible Product Expiration Date-CLOSED FDA-2002-P-0246 | Petition Denial from FDA Associate Commissioner for Regulatory Affairs to Auishalom Klammer | Other | PDN-Petition Denial | 2006-12-21T05:00:00Z | 2006 | 12 | 2024-08-15T13:51:59Z | 0 | 0 | 090000648049aa59 | |||
| FDA-2006-N-0543-0019 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable Richard G. Lugar | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-11T23:15:33Z | 0 | 0 | 09000064804690aa | |||
| FDA-2006-N-0543-0018 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable John Warner - Letter | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2009-02-17T23:03:30Z | 0 | 0 | 09000064804690a9 | |||
| FDA-2006-P-0267-0001 | FDA | Withdrawal of Approval of and recall all available stock of Ziana; CLOSED FDA-2006-P-0267 | Acknowledgment Letter from FDA DMB to Emil Tanghetti, MD | Other | Acknowledgement Letter/Receipt | 2006-12-20T05:00:00Z | 2006 | 12 | 2025-01-27T14:47:27Z | 0 | 0 | 0900006480457d63 | |||
| FDA-1978-N-0023-0008 | FDA | Skin Bleaching Drug Products- OPEN FDA-1978-N-0023 | Internal Memo from Jeffery Shuren, FDA/Office of the Commissioner, to FDA/DDM (HFA-305) dated December 19, 2006 | Other | Memorandum | 2006-12-20T05:00:00Z | 2006 | 12 | 2019-10-11T16:36:58Z | 0 | 0 | 090000648055f84b | |||
| FDA-2006-N-0543-0020 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Kathleen HArner | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-11T23:15:42Z | 0 | 0 | 09000064804690ab | |||
| FDA-2006-N-0543-0017 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable George Allen - Letter | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2009-02-17T23:01:37Z | 0 | 0 | 09000064804690a8 | |||
| FDA-2006-N-0543-0016 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable Evan Bayh | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-11T23:15:16Z | 0 | 0 | 09000064804690a7 | |||
| FDA-2006-N-0543-0013 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable Patty Murray - Letter | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2009-02-19T21:43:10Z | 0 | 0 | 09000064804690a4 | |||
| FDA-2003-D-0030-0012 | FDA | Guidance on Marketed Unapproved Drugs Compliance Policy Guide FDA-2003-D-0030 | FDA | Notice | N-Notice | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-12T00:54:03Z | 0 | 0 | 090000648048154e | |||
| FDA-2006-N-0420-0002 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Product Jurisdiction: Assignment of Agency Component for Review of Premarket Applications FDA-2006-N-0420 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Product Jurisdiction: Assignment of Agency Component for Review of Premarket Applications | Notice | General Notice | 2006-12-20T05:00:00Z | 2006 | 12 | 2006-12-20T05:00:00Z | 2007-01-20T04:59:59Z | 2025-06-18T22:33:57Z | E6-21636 | 0 | 0 | 09000064804617a1 |
| FDA-2006-P-0203-0005 | FDA | Exclusivity Determination for Risperidone FDA-2006-P-0203 | Interim Response from FDA CDER to Mylan Pharmaceuticals, Inc. | Other | Letter(s) | 2006-12-20T05:00:00Z | 2006 | 12 | 2024-11-21T13:46:24Z | 0 | 0 | 09000064804510d6 | |||
| FDA-2006-N-0543-0014 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Kathleen HArner | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-11T23:15:42Z | 0 | 0 | 09000064804690a5 | |||
| FDA-2006-N-0543-0015 | FDA | Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 | FDA to Honorable Rick Santorum | Other | LET-Letter | 2006-12-20T05:00:00Z | 2006 | 12 | 2008-04-11T23:15:07Z | 0 | 0 | 09000064804690a6 | |||
| FDA-2006-N-0046-0005 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 FDA-2006-N-0046 | FDA | Notice | N-Notice | 2006-12-20T05:00:00Z | 2006 | 12 | 2006-12-19T05:00:00Z | 2008-04-11T23:09:21Z | 0 | 0 | 0900006480443f99 | ||
| FDA-2006-P-0267-0002 | FDA | Withdrawal of Approval of and recall all available stock of Ziana; CLOSED FDA-2006-P-0267 | Acknowledgment Letter from FDA DMB to Emil Tanghetti, MD | Other | Acknowledgement Letter/Receipt | 2006-12-20T05:00:00Z | 2006 | 12 | 2025-01-27T14:48:57Z | 0 | 0 | 0900006480457d8d | |||
| FDA-2006-P-0025-0002 | FDA | Require ANDA Applicant for Generic of Eloxatin Solution as Reference Drug to Perform Clinical Testing-CLOSED FDA-2006-P-0025 | FDA/DDM to Sanofi-aventis US LLP | Other | ACK-Acknowledgement Letter | 2006-12-19T05:00:00Z | 2006 | 12 | 2008-04-11T23:17:24Z | 0 | 0 | 0900006480441f21 | |||
| FDA-1977-N-0013-0001 | FDA | Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Use; Proposed Amendment of the Tentative Final Monograph; Required Warnings and Other Labeling - OPEN FDA-1977-N-0013 | Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Required Warnings and Other Labeling | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2006-12-19T05:00:00Z | 2006 | 12 | 2006-12-19T05:00:00Z | 2007-06-20T03:59:59Z | 2019-03-23T23:59:29Z | E6-21855 | 0 | 0 | 09000064805d7f3f |
| FDA-2006-P-0025-0001 | FDA | Require ANDA Applicant for Generic of Eloxatin Solution as Reference Drug to Perform Clinical Testing-CLOSED FDA-2006-P-0025 | FDA/DDM to Sanofi-aventis US LLP | Other | ACK-Acknowledgement Letter | 2006-12-19T05:00:00Z | 2006 | 12 | 2008-04-11T23:17:24Z | 0 | 0 | 0900006480441ef8 | |||
| FDA-2006-P-0334-0004 | FDA | Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 | Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest | Other | Acknowledgement Letter/Receipt | 2006-12-19T05:00:00Z | 2006 | 12 | 2025-01-27T16:14:34Z | 0 | 0 | 090000648045d310 | |||
| FDA-2003-N-0049-0025 | FDA | Patient Examination & Surgeons' Gloves; Test Procedures FDA-2003-N-0049 | FDA | Notice | NFR-Notice of Final Rule | 2006-12-19T05:00:00Z | 2006 | 12 | 2006-12-18T05:00:00Z | 2008-04-12T00:58:18Z | 0 | 0 | 0900006480481999 | ||
| FDA-2006-P-0334-0003 | FDA | Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 | Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest | Other | Acknowledgement Letter/Receipt | 2006-12-19T05:00:00Z | 2006 | 12 | 2025-01-27T16:10:25Z | 0 | 0 | 090000648045d30f | |||
| FDA-2006-P-0387-0003 | FDA | FDA-2006-P-0387 | FDA Interim Reponse to Orchid Healthcare | Other | LET-Letter | 2006-12-18T05:00:00Z | 2006 | 12 | 2009-04-01T16:00:56Z | 0 | 0 | 0900006480460607 | |||
| FDA-2006-P-0346-0002 | FDA | FDA-2006-P-0346 | See FDA-2006-P-0346-0001 | Supporting & Related Material | Acknowledgement Letter/Receipt | 2006-12-18T05:00:00Z | 2006 | 12 | 2012-04-18T23:14:41Z | 0 | 0 | 090000648045f263 | |||
| FDA-2006-D-0158-0009 | FDA | Manufactured Food Regulatory Program Standards FDA-2006-D-0158 | FDA | Notice | N-Notice | 2006-12-18T05:00:00Z | 2006 | 12 | 2006-12-15T05:00:00Z | 2008-04-11T23:03:17Z | 0 | 0 | 0900006480450675 | ||
| FDA-2006-V-0221-0001 | FDA | FDA-2006-V-0221 | FDA/DDM to Mountain High Resort | Other | ACK-Acknowledgement Letter | 2006-12-18T05:00:00Z | 2006 | 12 | 2008-04-11T23:22:27Z | 0 | 0 | 09000064804520fb | |||
| FDA-1995-V-0012-0002 | FDA | Laser Light Show FDA-1995-V-0012 | Laseronics Northwest dba Laseronics Design Interstellar | Other | VRA-Approval for Variance | 2006-12-18T05:00:00Z | 2006 | 12 | 2013-08-11T02:44:08Z | 0 | 0 | 090000648055847a | |||
| FDA-2006-V-0221-0002 | FDA | FDA-2006-V-0221 | FDA/DDM to Mountain High Resort | Other | ACK-Acknowledgement Letter | 2006-12-18T05:00:00Z | 2006 | 12 | 2008-04-11T23:22:27Z | 0 | 0 | 090000648045212b | |||
| FDA-2000-V-0217-0003 | FDA | Laser Light Show FDA-2000-V-0217 | FDA Center for Devices and Radiological Health to Laser Wizardry - Approval for Variance | Other | VRA-Approval for Variance | 2006-12-18T05:00:00Z | 2006 | 12 | 2008-05-06T14:59:45Z | 0 | 0 | 09000064804d4fb0 | |||
| FDA-2006-P-0346-0001 | FDA | FDA-2006-P-0346 | Acknowledgement Letter to Endo Pharmaceuticals Inc | Other | Acknowledgement Letter/Receipt | 2006-12-18T05:00:00Z | 2006 | 12 | 2012-04-18T22:43:25Z | 0 | 0 | 090000648045f22c | |||
| FDA-2005-P-0366-0004 | FDA | Require that generic version of Wellbutrin XL (bupropion hydrochloride extended-release tablets) meet specific criteria in order to be considered bioequivalent to Wellbutrin XL-CLOSED FDA-2005-P-0366 | Petition Approval from FDA/Associate Commissioner for Policy and Planning to Keller and Heckman LLP | Other | Approval | 2006-12-18T05:00:00Z | 2006 | 12 | 2025-04-24T18:45:27Z | 0 | 0 | 090000648044af45 | |||
| FDA-2006-P-0277-0001 | FDA | Stop All Approvals of Medical Devices Used for Implantable Lens Implants Including, But Not Limited to Phakic IOLs (PIOLs) & Collamar Lenses or to Place a Moratorium on Their Use-CLOSED FDA-2006-P-0277 | Acknowledgement Letter from FDA DMB to Michael Patterson | Supporting & Related Material | 2006-12-18T00:00:00Z | 2006 | 12 | 2025-01-27T15:18:03Z | 0 | 1 | 09000064804583ea | ||||
| FDA-2006-P-0277-0002 | FDA | Stop All Approvals of Medical Devices Used for Implantable Lens Implants Including, But Not Limited to Phakic IOLs (PIOLs) & Collamar Lenses or to Place a Moratorium on Their Use-CLOSED FDA-2006-P-0277 | Acknowledgement Letter from FDA DMB to Michael Patterson | Other | 2006-12-18T00:00:00Z | 2006 | 12 | 2025-01-27T15:12:27Z | 0 | 1 | 090000648045840f | ||||
| FDA-2006-N-0498-0002 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Possible Footnotes and Cueing Schemes to Help Consumers Interpret Quantitative Trans Fat Disclosure on the Nutrition Facts Panel FDA-2006-N-0498 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Experimental Study of Possible Footnotes and Cueing Schemes to Help Consumers Interpret Quantitative Trans Fat Disclosure on the Nutrition Facts Panel | Notice | General Notice | 2006-12-17T05:00:00Z | 2006 | 12 | 2006-12-18T05:00:00Z | 2006-12-19T04:59:59Z | 2025-05-19T21:37:55Z | E6-21486 | 0 | 0 | 0900006480463888 |
| FDA-2006-V-0098-0005 | FDA | FDA-2006-V-0098 | N9NE Group dba Moon Bar - Approval for a Variance | Other | VRA-Approval for Variance | 2006-12-15T05:00:00Z | 2006 | 12 | 2008-09-09T12:57:35Z | 0 | 0 | 0900006480444cfb | |||
| FDA-2006-N-0370-0002 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 FDA-2006-N-0370 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Registration of Food Facilities Under the Public Health Security and Bloterrorism Preparedness and Response Act of 2002 | Notice | General Notice | 2006-12-15T05:00:00Z | 2006 | 12 | 2006-12-15T05:00:00Z | 2007-01-17T04:59:59Z | 2025-06-17T21:38:04Z | E6-21375 | 0 | 0 | 090000648045fe30 |
| FDA-2006-E-0197-0001 | FDA | Patent Extension Application for SPRYCEL (dasatinib), U.S. Patent No. 6,596,746 FDA-2006-E-0197 | Letter from U.S. Patent and Trademark Office to FDA CDER | Other | Letter(s) | 2006-12-15T05:00:00Z | 2006 | 12 | 2025-12-19T00:01:54Z | 0 | 0 | 0900006480450eec | |||
| FDA-2006-P-0010-0003 | FDA | Refain From Approving all Abbreviated Applications for Generic Enrofloxacin That Purport to Copy Bayer's Baytril 100 Injectable Solution-CLOSED FDA-2006-P-0010 | Interim Response from FDA CVM to Sidley Austin LLP | Other | Letter(s) | 2006-12-15T05:00:00Z | 2006 | 12 | 2024-10-28T17:16:53Z | 0 | 0 | 090000648044158b | |||
| FDA-1978-N-0018-0493 | FDA | Sunscreen Drug Products -OPEN FDA-1978-N-0018 | Letter from FDA/CDER to Schering-Plough Consumer Healthcare | Other | Letter(s) | 2006-12-15T05:00:00Z | 2006 | 12 | 2019-08-02T16:36:22Z | 0 | 0 | 090000648055aa60 | |||
| FDA-2006-V-0098-0006 | FDA | FDA-2006-V-0098 | FDA/CDRH to N9NE Group dba Moon Bar - Variance Attachment B | Other | VRA-Approval for Variance | 2006-12-15T05:00:00Z | 2006 | 12 | 2008-09-09T14:09:39Z | 0 | 0 | 0900006480444cfd | |||
| FDA-2006-N-0483-0001 | FDA | International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization Scheduling Recommendations for Dronabinol (INN) and its Stereoisomers, and Oripavine FDA-2006-N-0483 | International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization Scheduling Recommendations for Dronabinol and its Stereolsomers, and Oripavine | Notice | General Notice | 2006-12-15T05:00:00Z | 2006 | 12 | 2006-12-14T05:00:00Z | 2007-01-17T04:59:59Z | 2025-07-09T00:08:54Z | E6-21318 | 0 | 0 | 0900006480463157 |
| FDA-2006-E-0197-0002 | FDA | Patent Extension Application for SPRYCEL (dasatinib), U.S. Patent No. 6,596,746 FDA-2006-E-0197 | Notice of Informalities from U.S. Patent and Trademark Office to Bristol-Myers Squibb Company | Other | Letter(s) | 2006-12-15T05:00:00Z | 2006 | 12 | 2025-12-19T00:04:01Z | 0 | 0 | 0900006480450ef7 | |||
| FDA-2006-P-0404-0002 | FDA | FDA-2006-P-0404 | FDA/CFSAN to Hyman Phelps & McNamara PC | Other | LET-Letter | 2006-12-15T05:00:00Z | 2006 | 12 | 2008-04-11T23:21:26Z | 0 | 0 | 0900006480460d51 | |||
| FDA-2006-V-0098-0004 | FDA | FDA-2006-V-0098 | N9NE Group dba Moon Bar - Variance Attachment A | Other | VRA-Approval for Variance | 2006-12-15T05:00:00Z | 2006 | 12 | 2008-09-09T14:20:13Z | 0 | 0 | 0900006480444cf8 | |||
| FDA-2001-V-0064-0001 | FDA | Laser light show projector FDA-2001-V-0064 | FDA/CDRH Response to Nth Degree Creative - Approval for Variance | Other | VRA-Approval for Variance | 2006-12-15T05:00:00Z | 2006 | 12 | 2009-05-23T00:49:19Z | 0 | 0 | 09000064804b8141 | |||
| FDA-2006-N-0234-0001 | FDA | Drug Products Containing Quinine; Enforcement Action Dates FDA-2006-N-0234 | Drug Products Containing Quinine; Enforcement Action Dates | Notice | General Notice | 2006-12-15T05:00:00Z | 2006 | 12 | 2006-12-15T05:00:00Z | 2025-07-09T00:02:25Z | 06-9713 | 0 | 0 | 09000064804568dc | |
| FDA-1999-E-0123-0001 | FDA | Patent Term Extension for Uvadex, U.S. Patent No. 4,999,375 FDA-1999-E-0123 | Letter from FDA/CDER to the USPTO | Other | Letter(s) | 2006-12-15T00:00:00Z | 2006 | 12 | 2025-05-14T15:34:58Z | 0 | 0 | 09000064804ae996 | |||
| FDA-2006-N-0107-0003 | FDA | Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 | Duplicate | Other | LST-List | 2006-12-14T05:00:00Z | 2006 | 12 | 2008-11-18T22:36:08Z | 0 | 0 | 090000648044f71c | |||
| FDA-2006-N-0107-0005 | FDA | Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 | Duplicate | Other | LST-List | 2006-12-14T05:00:00Z | 2006 | 12 | 2008-11-18T22:40:24Z | 0 | 0 | 090000648044f720 | |||
| FDA-2006-P-0214-0001 | FDA | Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822 FDA-2006-P-0214 | Acknowledgment Letter from FDA DMB to Kleinfeld, Kaplan and Becker, LLP | Other | Acknowledgement Letter/Receipt | 2006-12-14T05:00:00Z | 2006 | 12 | 2024-12-09T14:30:53Z | 0 | 0 | 0900006480451d15 | |||
| FDA-2006-P-0214-0002 | FDA | Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822 FDA-2006-P-0214 | Acknowledgment Letter from FDA DMB to Kleinfeld, Kaplan and Becker, LLP | Other | Acknowledgement Letter/Receipt | 2006-12-14T05:00:00Z | 2006 | 12 | 2024-12-09T14:34:53Z | 0 | 0 | 0900006480451d47 | |||
| FDA-2006-P-0271-0001 | FDA | Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness - CLOSED FDA-2006-P-0271 | Acknowledgment Letter from FDA DMB to Caraco Pharmaceutical Laboratories, Ltd. | Other | Acknowledgement Letter/Receipt | 2006-12-14T05:00:00Z | 2006 | 12 | 2025-01-27T15:43:34Z | 0 | 0 | 090000648045806e | |||
| FDA-2006-P-0271-0002 | FDA | Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness - CLOSED FDA-2006-P-0271 | Acknowledgment Letter from FDA DMB to Caraco Pharmaceutical Laboratories, Ltd. | Other | Acknowledgement Letter/Receipt | 2006-12-14T05:00:00Z | 2006 | 12 | 2025-01-27T15:49:44Z | 0 | 0 | 0900006480458073 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);